LogicBio Therapeutics (NASDAQ:LOGC) announces a research collaboration with Takeda Pharmaceutical (OTCPK:TKPHF) to further develop LB-301 for the treatment of Crigler-Najjar syndrome.
Under the agreement, Takeda will provide funding for the research program and will have an exclusive option to negotiate an exclusive, worldwide license to LogicBio’s LB-301 program.
LB-301 is a recombinant adeno-associated viral vector with a uridine disphosphate-glucuronosyltransferase-1 gene leveraging GeneRide genome editing platform for the treatment of Crigler-Najjar syndrome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.